Watch videos to learn more about the Cologuard® test and colorectal cancer (CRC) screening
The Cologuard journey
Hear the game-changing story of developing the Cologuard test, the first and only method using mt-sDNA technology to screen for CRC and precancerous polyps. From having one of the largest clinical trials for a diagnostic tool up to that point, to getting FDA approval and Medicare coverage on the same day, to being included in United States Preventive Services Task Force (USPSTF) and American Cancer Society (ACS) guidance, Exact Sciences and the Cologuard test have brought innovation to CRC screening. Since 2014, healthcare providers have prescribed millions of Cologuard tests, leading to better outcomes for >13 million patients.1-4*†
Cologuard Roundtable National Broadcast
The Closing the Screening Gap One Patient at a Time broadcast is a multispecialty discussion between experts about CRC and the Cologuard test as a screening option. These experts include Dr Raymond Wadlow, a gastrointestinal oncologist at the Inova Schar Cancer Institute, Dr Daniel Neumann, the president and CEO of Capital Digestive Care, LLC, Dr Lillian Schapiro, a gynecologist at Ideal Gynecology, and Dr Timothy Quinn, a medical director at Quinn Healthcare.
All panelists are paid speakers, presenting on behalf of Exact Sciences. Views, opinions, and information provided during this presentation are based on the speakers’ own clinical practice and experience and are not clinical, diagnostic, or treatment advice for any particular event. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.
Dr Fenton shares his story of CRC screening
Dr Fenton is a primary care physician at Beth Israel Deaconess Medical Center in Salem, NH. After becoming eligible for CRC screening, he used the Cologuard test and received a positive result. He followed the proper steps, was treated for stage I CRC, and is now cancer free.
USPSTF recommends screening average-risk patients at 45+ (Grade B recommendation)3‡
Dr Limburg holds the academic rank of Professor of Medicine in the Mayo Clinic College of Medicine and serves as Chief Medical Officer for Screening at Exact Sciences. Listen to him review changes to the USPSTF guidelines and the impact these changes have.
- English (US)
- English (US)
- Español (Spanish)
- العربية (Arabic)
- Français (French)
- Kreyòl Ayisyen (Haitian Creole)
- हिंदी (Hindi)
- 한국어 (Korean)
- Português (Portuguese)
- Русский (Russian)
- Tagalog/Filipino
- 粵語 (Cantonese Chinese)
- Tiếng Việt (Vietnamese)
- 国语 (Mandarin Chinese)
Exact Sciences
Laboratories virtual lab tour
Take a virtual tour for a sneak peek inside Exact Sciences Laboratories in Madison, WI. Learn how this innovative and customer-focused facility delivers CRC screening results for eligible patients nationwide. Discover that no matter how far apart we are, patients are still within reach.
Meet Alex, 63
Alex is a 63-year-old hypothetical patient, and his barrier to CRC screening is discomfort with colonoscopy prep and the procedure itself. Watch how the Cologuard test helped him overcome this barrier.
Cologuard resources
Find resources for you, your practice, and your eligible patients.
Cologuard events
Find events near where you can learn more about the Cologuard test
- The USPSTF found adequate evidence that screening eligible patients aged 45 to 49 years provides a moderate benefit in reducing CRC deaths and increasing life-years gained. USPSTF-recommended screening modalities include stool-based tests or direct visualization tests.3
- The ACS makes a qualified recommendation for screening in eligible patients aged 45 to 49 years, indicating clear evidence of benefit of screening but less certainty about the balance of benefits, harms, and patient preferences. ACS-recommended screening modalities include high-sensitivity stool-based tests or structural (visual) examinations.4
- The USPSTF concludes with moderate certainty that screening for CRC in adults aged 45-49 years has moderate net benefit (Grade B).3